578 related articles for article (PubMed ID: 16920551)
1. Receptor activator NFkappaB-ligand and osteoprotegerin protein expression in human periapical cysts and granulomas.
Menezes R; Bramante CM; da Silva Paiva KB; Letra A; Carneiro E; Fernando Zambuzzi W; Granjeiro JM
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Sep; 102(3):404-9. PubMed ID: 16920551
[TBL] [Abstract][Full Text] [Related]
2. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
Stilgren LS; Rettmer E; Eriksen EF; Hegedüs L; Beck-Nielsen H; Abrahamsen B
Bone; 2004 Jul; 35(1):256-65. PubMed ID: 15207766
[TBL] [Abstract][Full Text] [Related]
3. RANKL in human periapical granuloma: possible involvement in periapical bone destruction.
Vernal R; Dezerega A; Dutzan N; Chaparro A; León R; Chandía S; Silva A; Gamonal J
Oral Dis; 2006 May; 12(3):283-9. PubMed ID: 16700737
[TBL] [Abstract][Full Text] [Related]
4. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis.
Catrina AI; af Klint E; Ernestam S; Catrina SB; Makrygiannakis D; Botusan IR; Klareskog L; Ulfgren AK
Arthritis Rheum; 2006 Jan; 54(1):76-81. PubMed ID: 16385498
[TBL] [Abstract][Full Text] [Related]
5. Intraarticular corticosteroids decrease synovial RANKL expression in inflammatory arthritis.
Makrygiannakis D; af Klint E; Catrina SB; Botusan IR; Klareskog E; Klareskog L; Ulfgren AK; Catrina AI
Arthritis Rheum; 2006 May; 54(5):1463-72. PubMed ID: 16646024
[TBL] [Abstract][Full Text] [Related]
6. Lipopolysaccharide stimulates expression of osteoprotegerin and receptor activator of NF-kappa B ligand in periodontal ligament fibroblasts through the induction of interleukin-1 beta and tumor necrosis factor-alpha.
Wada N; Maeda H; Yoshimine Y; Akamine A
Bone; 2004 Sep; 35(3):629-35. PubMed ID: 15336598
[TBL] [Abstract][Full Text] [Related]
7. Expression of RANKL and OPG in middle ear cholesteatoma tissue.
Jeong JH; Park CW; Tae K; Lee SH; Shin DH; Kim KR; Park YW
Laryngoscope; 2006 Jul; 116(7):1180-4. PubMed ID: 16826057
[TBL] [Abstract][Full Text] [Related]
8. Megakaryocytes modulate osteoblast synthesis of type-l collagen, osteoprotegerin, and RANKL.
Bord S; Frith E; Ireland DC; Scott MA; Craig JI; Compston JE
Bone; 2005 May; 36(5):812-9. PubMed ID: 15794927
[TBL] [Abstract][Full Text] [Related]
9. Identification of the osteoprotegerin/receptor activator of nuclear factor-kappa B ligand system in gingival crevicular fluid and tissue of patients with chronic periodontitis.
Lu HK; Chen YL; Chang HC; Li CL; Kuo MY
J Periodontal Res; 2006 Aug; 41(4):354-60. PubMed ID: 16827732
[TBL] [Abstract][Full Text] [Related]
10. Effects of dissociated glucocorticoids on OPG and RANKL in osteoblastic cells.
Humphrey EL; Williams JH; Davie MW; Marshall MJ
Bone; 2006 May; 38(5):652-61. PubMed ID: 16298558
[TBL] [Abstract][Full Text] [Related]
11. Factors involved in the T helper type 1 and type 2 cell commitment and osteoclast regulation in inflammatory apical diseases.
Fukada SY; Silva TA; Garlet GP; Rosa AL; da Silva JS; Cunha FQ
Oral Microbiol Immunol; 2009 Feb; 24(1):25-31. PubMed ID: 19121066
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen.
Bord S; Frith E; Ireland DC; Scott MA; Craig JI; Compston JE
Br J Haematol; 2004 Jul; 126(2):244-51. PubMed ID: 15238146
[TBL] [Abstract][Full Text] [Related]
13. Osteoprotegerin (OPG) and RANKL expression and distribution in developing human craniomandibular joint.
Carda C; Silvestrini G; Gomez de Ferraris ME; Peydró A; Bonucci E
Tissue Cell; 2005 Jun; 37(3):247-55. PubMed ID: 15899507
[TBL] [Abstract][Full Text] [Related]
14. Mechanical stimulation effects on functional end effectors in osteoblastic MG-63 cells.
Saunders MM; Taylor AF; Du C; Zhou Z; Pellegrini VD; Donahue HJ
J Biomech; 2006; 39(8):1419-27. PubMed ID: 15953606
[TBL] [Abstract][Full Text] [Related]
15. [Effects of 1,25-dihydroxyvitamin D3 on the expressions of osteoprotegerin and receptor activator of NF-kappaB ligand in mouse osteoblasts].
Tian QX; Huang GY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Aug; 26(4):418-22. PubMed ID: 15379268
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of osteoprotegerin production in bone marrow macrophages by macrophage colony-stimulating factor.
Yamada N; Tsujimura T; Ueda H; Hayashi S; Ohyama H; Okamura H; Terada N
Cytokine; 2005 Aug; 31(4):288-97. PubMed ID: 15996478
[TBL] [Abstract][Full Text] [Related]
17. Increased expression of IL-6 and RANK mRNA in human trabecular bone from fragility fracture of the femoral neck.
Tsangari H; Findlay DM; Kuliwaba JS; Atkins GJ; Fazzalari NL
Bone; 2004 Jul; 35(1):334-42. PubMed ID: 15207775
[TBL] [Abstract][Full Text] [Related]
18. [RANKL/RANK, OPG and OPT in a group of patients affected by chronic arthritis. Preliminary report].
Minenna G; D'Amore S; Maggiolini P; Scagliusi P; D'Amore M
Recenti Prog Med; 2005 Sep; 96(9):431-2. PubMed ID: 16229324
[TBL] [Abstract][Full Text] [Related]
19. Comparative immunohistochemical expression of RANK, RANKL and OPG in radicular and dentigerous cysts.
de Moraes M; de Lucena HF; de Azevedo PR; Queiroz LM; Costa Ade L
Arch Oral Biol; 2011 Nov; 56(11):1256-63. PubMed ID: 21683340
[TBL] [Abstract][Full Text] [Related]
20. Dysregulated osteoprotegerin/RANK ligand/RANK axis in clinical and experimental heart failure.
Ueland T; Yndestad A; Øie E; Florholmen G; Halvorsen B; Frøland SS; Simonsen S; Christensen G; Gullestad L; Aukrust P
Circulation; 2005 May; 111(19):2461-8. PubMed ID: 15883214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
